This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to ...

VANCOUVER, BC / ACCESS Newswire / November 4, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, ...